A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study Evaluating The Efficacy And Safety Of Filgotinib In The Treatment Of Small Bowel Crohn’s Disease (SBCD).
Principal Investigator(s)
Email for information
Funded by
Geneva
Research Start Date
Status
Active
This is a Phase 2 randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of filgotinib in treating subjects with SBCD. Approximately 100 subjects aged 18 to 75 years with SBCD will be randomized to 1 of 3 treatment groups in a 2:2:1 ratio to receive filgotinib 200 mg, filgotinib 100 mg or matching placebo.
The appearance of name-brand products in this article does not constitute endorsement by Brooke Army Medical Center, the U.S. Army Medical Center, the U.S. Army Medical Department, the U.S. Army Office of the Surgeon General, the Department of the Army, the Department of Defense, or the U.S. Government of the information, products, or services contained therein.